| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 9,540 | $40 | $362.6K |
| J0897 | Injection, denosumab, 1 mg | 6,000 | $20 | $114K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31,800 | $1 | $63.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 510 | $110 | $54.7K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 38,250 | $1 | $38.3K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 380 | $80 | $30K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 190 | $150 | $29.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 210 | $120 | $24.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 130 | $60 | $8.4K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 60 | $100 | $6.5K |